Literature DB >> 31037763

Cancer drug resistance: A fleet to conquer.

Showket Hussain1, Ankita Singh1, Sheeraz Un Nazir1, Sonam Tulsyan2, Asiya Khan3, Ramesh Kumar4, Nasreena Bashir5, Pranay Tanwar3, Ravi Mehrotra2.   

Abstract

Cancer is a disease that claims millions of lives each year across the world. Despite advancement in technologies and therapeutics for treating the disease, these modes are often found to turn ineffective during the course of treatment. The resistance against drugs in cancer patients stems from multiple factors, which constitute genetic heterogeneity like gene mutations, tumor microenvironment, exosomes, miRNAs, high rate of drug efflux from cells, and so on. This review attempts to collate all such known and reported factors that influence cancer drug resistance and may help researchers with information that might be useful in developing better therapeutics in near future to enable better management of several cancers across the world.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  alternate signaling pathway; cancer drug resistance; exosomes; miRNAs; tumor microenvironment

Year:  2019        PMID: 31037763     DOI: 10.1002/jcb.28782

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  14 in total

1.  A previously identified apoptosis inhibitor iASPP confers resistance to chemotherapeutic drugs by suppressing senescence in cancer cells.

Authors:  Huayi Li; Wenxin Zhang; Kunming Zhao; Dong Zhao; Shanliang Zheng; Ying Hu
Journal:  J Biol Chem       Date:  2020-01-31       Impact factor: 5.157

Review 2.  Materials-driven approaches to understand extrinsic drug resistance in cancer.

Authors:  Justin R Pritchard; Michael J Lee; Shelly R Peyton
Journal:  Soft Matter       Date:  2022-05-11       Impact factor: 4.046

Review 3.  Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.

Authors:  Lei Zhong; Yueshan Li; Liang Xiong; Wenjing Wang; Ming Wu; Ting Yuan; Wei Yang; Chenyu Tian; Zhuang Miao; Tianqi Wang; Shengyong Yang
Journal:  Signal Transduct Target Ther       Date:  2021-05-31

4.  Orosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 9.

Authors:  Luo Qiong; Jun Yin
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Evaluation of the anticarcinogenic potential of the endophyte, Streptomyces sp. LRE541 isolated from Lilium davidii var. unicolor (Hoog) Cotton.

Authors:  Aiai Ma; Kan Jiang; Bin Chen; Shasha Chen; Xinge Qi; Huining Lu; Junlin Liu; Xuan Zhou; Tan Gao; Jinhui Li; Changming Zhao
Journal:  Microb Cell Fact       Date:  2021-12-04       Impact factor: 5.328

Review 6.  Saikosaponin D: review on the antitumour effects, toxicity and pharmacokinetics.

Authors:  Piao Zhou; Wei Shi; Xiao-Yan He; Quan-Yu Du; Fei Wang; Jing Guo
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

Review 7.  Leveraging microenvironmental synthetic lethalities to treat cancer.

Authors:  Kevin J Metcalf; Alaa Alazzeh; Zena Werb; Valerie M Weaver
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

8.  Low Expression of Smurf1 Enhances the Chemosensitivity of Human Colorectal Cancer to Gemcitabine and Cisplatin in Patient-Derived Xenograft Models.

Authors:  Jing Guo; Guiying Xu; Chuanbin Mao; Rongfei Wei
Journal:  Transl Oncol       Date:  2020-06-05       Impact factor: 4.243

9.  Targeting poor proteasomal function with radioiodine eliminates CT26 colon cancer stem cells resistant to bortezomib therapy.

Authors:  Jin Hee Lee; Kyung-Ho Jung; Jin Won Park; Seung Hwan Moon; Young Seok Cho; Kyung-Han Lee
Journal:  Sci Rep       Date:  2020-08-31       Impact factor: 4.379

10.  Role of Bcl-2 on drug resistance in breast cancer polyploidy-induced spindle poisons.

Authors:  Bibo Yuan; Juan Hao; Qian Zhang; Yan Wang; Yu Zhu
Journal:  Oncol Lett       Date:  2020-01-07       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.